One such inhibitor is gusacitinib, a pan-JAK/ spleen tyrosine kinase (SYK) inhibitor that is being developed for AD (NCT03531957) and chronic hand eczema (NCT03728504). The gene discussed is SYK; the disease is Alzheimer disease.